Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

NMTC vs STEX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

NMTC Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 5–3 Matrix Metrics)

NMTC Overall Winner 6-Pillar Tally: NMTC 4 – 1 STEX (1 Tie) Matrix Metrics: NMTC 5 – 3 STEX

As of Nov 20, 2026, NeuroOne Medical Technologies Corporation (NMTC) is the stronger overall head-to-head candidate over Streamex Corp. (STEX) in the Tradestie Institutional Equity Comparison Engine, winning 5–3 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). NMTC carries a Unified Composite Score of 45.5/100 (HOLD) at $0.65 (N/M Forward P/E, -63.4% operating margin), whereas STEX carries 51.3/100 (HOLD) at $0.33 (N/M Forward P/E, -36966.7% operating margin).

  • Composite vs. Pillar Nuance: While STEX currently prints a higher short-term Unified Composite Score (51.3/100 HOLD vs. NMTC 45.5/100 HOLD), NMTC captures the overall institutional head-to-head verdict (5–3 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (-63.4% vs. -36966.7% operating margin) and revenue trajectory (+16.3% vs. +0.0% YoY).
  • Technical & Structure Timing Caution: NMTC is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 31.2); meanwhile STEX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 40.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About NMTC vs STEX
NMTC NASDAQ Head-to-Head Winner
NeuroOne Medical Technologies Corporation Common Stock
Surgical & Medical Instruments & Apparatus
$0.65
-3.38% 1D
Market Cap $6.1M
TTM Revenue $12M
Forward P/E N/M
Beta / 30D Vol 1.55β · 105% Vol
Unified Composite Score
45.5 / 100 HOLD
Tech 33.0 Fund 51.0 Flow 60.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -28.4%), weak momentum, RSI 31
RSI-14: 31.2 · SMA20: $0.83 · SMA50: $1.03
STEX NASDAQ
Streamex Corp. Common Stock
Electromedical & Electrotherapeutic Apparatus
$0.33
+8.54% 1D
Market Cap $56.2M
TTM Revenue $291,000
Forward P/E N/M
Beta / 30D Vol 1.71β · 127% Vol
Unified Composite Score
51.3 / 100 HOLD
Tech 68.0 Fund 63.0 Flow 72.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -25.8%), weak momentum, RSI 40
RSI-14: 40.4 · SMA20: $0.35 · SMA50: $0.48

6-Pillar Scorecard Institutional Category Breakdown (NMTC 4 – 1 STEX)

Columns: Metric · NMTC · STEX
1. Valuation Multiples NMTC
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 0.3x N/M
2. Growth & Scale NMTC
Revenue Growth (YoY) +16.3% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $12M $291,000
Market Cap $6.1M $56.2M
3. Profitability & Quality NMTC
Gross Margin 23.0% 100.0%
Operating Margin -63.4% -36966.7%
Net Profit Margin -59.7% 0.0%
Return on Equity (ROE) -124.7% -775.2%
4. Balance Sheet & Cash Flow NMTC
Cash Generation (TTM) -$7.6M -$30M
Cash Flow Margin -60.7% N/A
Net Cash / Leverage $2.6M Net Cash $4.8M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning STEX
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) 423.6% (61st %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Devices Operator Capital Markets Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: NMTC (5) vs STEX (3)
Institutional Metric NMTC STEX Criterion Row Edge
Market Capitalization
Scale
$6.1M $56.2M Larger Scale STEX
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+16.3% +0.0% Higher Growth NMTC
Operating Margin (TTM)
Profitability
-63.4% -36966.7% Higher Margin NMTC
Net Profit Margin
Profitability
-59.7% 0.0% Higher Margin STEX
Return on Equity (ROE)
Capital Efficiency
-124.7% -775.2% Higher ROE NMTC
52-Week Range Position
Momentum
2% ($1–$5) 2% ($0–$5) Stronger Trend NMTC
Beta / 30D Volatility
Risk Regime
1.55β · 105% Vol 1.71β · 127% Vol Lower Realized Risk NMTC
Unified Institutional Score
Composite Signal
45.5 / 100 (HOLD) 51.3 / 100 (HOLD) Higher Composite STEX
Trailing 12M Revenue (USD)
Operating Scale
$12M $291,000 FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
23.0% 100.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 0.3x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$7.6M ($2.6M Net Cash) -$30M ($4.8M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon STEX +24.9 pp
NMTC: -33.46% · STEX: -8.56%
3M Horizon STEX +12.24 pp
NMTC: -69.53% · STEX: -57.29%
6M Horizon STEX +7.85 pp
NMTC: -82.33% · STEX: -74.48%
1Y Horizon NMTC +94.81 pp
NMTC: +3.49% · STEX: -91.32%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period NMTC Revenue STEX Revenue NMTC Op. Margin STEX Op. Margin Margin Leader
FY2012 $0M N/A -1491.1% N/A NMTC
FY2013 $0M N/A -2009.0% N/A NMTC
FY2014 $0M N/A -4646.1% N/A NMTC
FY2021 $0M $0M -5735.9% -7576.2% NMTC
FY2022 $0M $0M -5860.2% -9533.2% NMTC
FY2023 $0M $0M -612.3% -158400.0% NMTC
FY2024 $0M $0M -344.3% -32155.0% NMTC
FY2025 $10M N/A -46.5% N/A NMTC

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
NMTC UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact NMTC Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
STEX UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 423.6%
IV Percentile 61st %ile
Put/Call OI Skew N/A
IV Regime Elevated (60th–80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact STEX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
NMTC Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $6.1M market capitalization and -63.4% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
STEX Moat Profile Cyclical / Execution-Driven Positioning
Capital Markets Operator
Competes within the Capital Markets value chain with $56.2M market capitalization and -36966.7% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ NMTC vs STEX Key Questions & Quantitative Answers

As of Nov 20, 2026, NeuroOne Medical Technologies Corporation (NMTC) is the stronger overall head-to-head candidate over Streamex Corp. (STEX) in the Tradestie Institutional Equity Comparison Engine, winning 5–3 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). NMTC carries a Unified Composite Score of 45.5/100 (HOLD) at $0.65 (N/M Forward P/E, -63.4% operating margin), whereas STEX carries 51.3/100 (HOLD) at $0.33 (N/M Forward P/E, -36966.7% operating margin). Composite vs. Pillar Nuance: While STEX currently prints a higher short-term Unified Composite Score (51.3/100 HOLD vs. NMTC 45.5/100 HOLD), NMTC captures the overall institutional head-to-head verdict (5–3 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (-63.4% vs. -36966.7% operating margin) and revenue trajectory (+16.3% vs. +0.0% YoY). Technical & Structure Timing Caution: NMTC is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 31.2); meanwhile STEX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 40.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

NMTC leads the Growth & Scale pillar: NMTC posts +16.3% YoY revenue growth and +0.0% YoY earnings growth on $12M TTM revenue (23.0% gross margin, -63.4% operating margin), compared with STEX at +0.0% YoY revenue growth and +0.0% YoY earnings growth on $291,000 TTM revenue (100.0% gross margin, -36966.7% operating margin). Across the 8-period historical trajectory (FY2012 to FY2025), NMTC cumulative revenue shifted N/A while STEX shifted N/A. In operating R&D and SG&A reinvestment, NMTC deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for STEX.

NMTC screens cheaper on headline valuation multiples. NMTC trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.3x EV/Revenue (-60.7% FCF margin), whereas STEX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against NMTC (-124.7% ROE) versus STEX (-775.2% ROE) capital efficiency.

In options market volatility and institutional positioning, NMTC carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.55β · 105% Vol realized risk). By comparison, STEX carries 423.6% implied volatility (61st %ile, Elevated (60th–80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.71β · 127% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.